Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Leukemia

    Tucson, AZ

    Search
    Leukemia
    Tucson, AZ
    Show Map
    Map View
    Tucson, AZ
    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      134 Leukemia Trials near Tucson, AZ

      Power is an online platform that helps thousands of Leukemia patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Gilteritinib vs Midostaurin for Acute Myeloid Leukemia

      Scottsdale, Arizona
      Eligible untreated patients with FLT3 acute myeloid leukemia (AML) between the ages of 18 and 70 will be randomized to receive gilteritinib or midostaurin during induction and consolidation. Patients will also receive standard chemotherapy of daunorubicin and cytarabine during induction and high-dose cytarabine during consolidation. Gilteritinib, is an oral drug that works by stopping the leukemia cells from making the FLT3 protein. This may help stop the leukemia cells from growing faster and thus may help make chemotherapy more effective. Gilteritinib has been approved by the Food and Drug Administration (FDA) for patients who have relapsed or refractory AML with a FLT3 mutation but is not approved by the FDA for newly diagnosed FLT3 AML, and its use in this setting is considered investigational. Midostaurin is an oral drug that works by blocking several proteins on cancer cells, including FLT3 that can help leukemia cells grow. Blocking this pathway can cause death to the leukemic cells. Midostaurin is approved by the FDA for the treatment of FLT3 AML. The purpose of this study is to compare the effectiveness of gilteritinib to midostaurin in patients receiving combination chemotherapy for FLT3 AML.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:M3 AML, CNS Leukemia, Others
      Must Not Be Taking:CYP3A Inducers, P-gp Inducers

      181 Participants Needed

      Ruxolitinib + Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia

      Phoenix, Arizona
      This randomized phase II trial studies how well ruxolitinib phosphate, and bosutnib, dasatinib, imatinib or nilotinib, work in treating patients with chronic myeloid leukemia. Chronic myeloid leukemia cells produce a protein called BCR-ABL. The BCR-ABL protein helps chronic myeloid leukemia cells to grow and divide. Tyrosine kinase inhibitors, such as bosutinib, dasatinib, and nilotinib, stop the BCR-ABL protein from working, which helps to reduce the amount of chronic myeloid leukemia cells in the body. Ruxolitinib is a different type of drug that helps to stop the body from making substances called growth factors. Chronic myeloid leukemia cells need growth factors to grow and divide. The addition of ruxolitinib to the tyrosine kinase inhibitor may or may not help reduce the amount of chronic myeloid leukemia cells in the body.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Nursing, TKI Resistance, Others
      Must Be Taking:Tyrosine Kinase Inhibitors

      84 Participants Needed

      NK Cell Infusions for Acute Myeloid Leukemia

      Phoenix, Arizona
      This trial is testing if giving special immune cells from a donor to children and young adults with high-risk AML can help their immune system fight cancer and infections better after a bone marrow transplant.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Phase 2
      Age:0 - 25

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Pregnancy, Prior Transplant, Others

      30 Participants Needed

      Pembrolizumab + TKI for Chronic Myeloid Leukemia

      Phoenix, Arizona
      This phase II trial studies how well pembrolizumab and dasatinib, imatinib mesylate, or nilotinib work in treating patients with chronic myeloid leukemia and persistent detection of minimal residual disease, defined as the levels of a gene product called bcr-abl in the blood. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Dasatinib, imatinib mesylate, and nilotinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and dasatinib, imatinib mesylate, or nilotinib may work better in treating patients with chronic myeloid leukemia.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Active Infection, Autoimmune Disease, Others
      Must Be Taking:TKIs

      40 Participants Needed

      BMF-500 for Leukemia

      Phoenix, Arizona
      This trial is testing BMF-500, a pill that blocks a protein called FLT3, in adults with aggressive types of leukemia. The goal is to stop cancer cells from growing by blocking this protein.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Cardiovascular Disease, High WBC, Pregnancy, Others
      Must Be Taking:Azole Antifungals

      35 Participants Needed

      Targeted Immunotherapy for Leukemia

      Phoeniz, Arizona
      A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolescents, and young adults (CAYA) with high risk T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LLy). Pre- and post-HCT NGS-MRD studies will be correlated with outcomes in children, adolescents, and young adults with T-ALL undergoing allogeneic HCT and post-HCT DARA treatment. The study will also evaluate T-cell repertoire and immune reconstitution prior to and following DARA post-HCT treatment and correlate with patient outcomes.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:< 39

      Key Eligibility Criteria

      Disqualifiers:HIV, Hepatitis B, Hepatitis C, Others

      30 Participants Needed

      Dasatinib for Pediatric Leukemia

      Phoenix, Arizona
      The purpose of this study is to determine whether dasatinib is safe and effective in children and adolescents with newly diagnosed chronic myeloid leukemia (CML), or in children with Ph+ acute lymphoblastic leukemia (ALL), accelerated or blast phases CML who relapse after imatinib or who are resistant or intolerant to imatinib. The side effects of this oral investigational drug in children and adolescents will be evaluated
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Age:1 - 18

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      130 Participants Needed

      Ziftomenib Combinations for Acute Myeloid Leukemia

      Phoenix, Arizona
      Ziftomenib is an investigational drug in development for the treatment of patients with acute myeloid leukemia (AML) with certain genetic alterations. This protocol has 3 separate arms that will investigate the benefits and risks of adding ziftomenib to standard-of-care (SOC) drug treatments in patients who have AML with certain genetic mutations. Both newly diagnosed and relapsed refractory patients with AML will be assigned to different cohorts based on specific study criteria and physician discretion. The purpose of this study is to assess the safety, tolerability, and early signs of efficacy of ziftomenib in combination with SOC drugs to treat AML.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Leukostasis, CNS Involvement, Active Infection, Others
      Must Not Be Taking:Live Vaccines

      420 Participants Needed

      Ibrutinib + Rituximab for Chronic Lymphocytic Leukemia

      Scottsdale, Arizona
      This phase III trial studies ibrutinib and rituximab to see how well they work compared to fludarabine phosphate, cyclophosphamide, and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as fludarabine phosphate and cyclophosphamide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. It is not yet known whether fludarabine phosphate, cyclophosphamide, and rituximab may work better than ibrutinib and rituximab in treating patients with untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Congestive Heart Failure, Hepatitis B, Others
      Must Not Be Taking:CYP3A Inhibitors, Warfarin

      529 Participants Needed

      Acalabrutinib +/- Obinutuzumab for Chronic Lymphocytic Leukemia

      Scottsdale, Arizona
      This phase II trials studies how well acalabrutinib with or without obinutuzumab works in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma. Acalabrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. It is not yet known whether giving acalabrutinib with or without obinutuzumab will work better in treating patients with early-stage chronic lymphocytic leukemia or small lymphocytic lymphoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:CNS Lymphoma, Active Infection, Others
      Must Not Be Taking:Antiretrovirals, Anticoagulants, CYP3A Inducers

      120 Participants Needed

      Venetoclax + ASTX727 for Chronic Myelomonocytic Leukemia

      Phoenix, Arizona
      This trial is testing if a combination of two drugs, ASTX727 and venetoclax, is more effective than ASTX727 alone in treating certain bone marrow cancers. It focuses on patients with CMML and MDS/MPN who have too many immature blood cells. ASTX727 helps produce normal blood cells and kills abnormal ones, while venetoclax blocks a protein that cancer cells need to survive. Venetoclax is an anticancer drug used to treat lymphomas and leukemias, but it has severe side effects.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, CNS Disease, Active Infection, Others
      Must Not Be Taking:Lenalidomide, Decitabine, Azacitidine, Others

      132 Participants Needed

      Venetoclax + Vincristine for Acute Lymphoblastic Leukemia

      Scottsdale, Arizona
      This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with vincristine in treating patients with T-cell or B-cell acute lymphoblastic leukemia that has come back (recurrent) or does not respond to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Chemotherapy drugs, such as vincristine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving venetoclax together with vincristine may work better in treating patients with acute lymphoblastic leukemia compared to vincristine alone.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, CNS Leukemia, Burkitt's, Others
      Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers

      74 Participants Needed

      CYT-0851 for Cancer

      Scottsdale, Arizona
      This trial is testing a new drug called CYT-0851 in patients with certain types of cancer that have not responded to other treatments. The goal is to see if the drug is safe and understand how it works in the body.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      170 Participants Needed

      Reduced-Dose Cyclophosphamide for Leukemia After Stem Cell Transplant

      Scottsdale, Arizona
      The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question\[s\] it aims to answer are: * Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? * Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Prior Allogeneic Transplant, Uncontrolled Infection, Others

      313 Participants Needed

      AG-120 for Blood Cancers

      Phoenix, Arizona
      The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of patients will receive AG-120 to further evaluate the safety, tolerability, and clinical activity of the recommended Phase II dose. Additionally, the study includes a substudy evaluating the safety and tolerability, clinical activity, pharmacokinetics, and pharmacodynamics of AG-120 in subjects with relapsed or refractory myelodysplastic syndrome with an IDH1 mutation. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Recent HSCT, Severe Infection, Heart Failure, Others
      Must Not Be Taking:QT Prolonging Drugs

      291 Participants Needed

      Genomic Studies for Early Detection of Myeloid Leukemia or Bone Marrow Failure Syndrome

      Scottsdale, Arizona
      This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Under 18 Years

      2000 Participants Needed

      EP31670 for Advanced Cancer

      Phoenix, Arizona
      A Phase 1, first-in-human study of EP31670, a dual BET and CBP/p300 inhibitor in patients with targeted advanced solid tumors and Hematological Malignancies
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Metastasis, Heart Failure, Others
      Must Not Be Taking:Antibiotics, Antifungals

      75 Participants Needed

      CTX131 for Blood Cancers

      Phoenix, Arizona
      This is an open label, multicenter, phase 1/2 dose evaluation and cohort expansion study evaluating the safety and efficacy of CTX131 in subjects with Relapsed/Refractory Hematologic Malignancies
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:CNS Pathology, Uncontrolled Infection, HIV, Others
      Must Not Be Taking:Anticancer Biologics, Non-biological Anticancer

      290 Participants Needed

      Vitamin D for Lymphoma

      Scottsdale, Arizona
      This partially randomized clinical trial studies cholecalciferol in improving survival in patients with newly diagnosed cancer with vitamin D insufficiency. Vitamin D replacement may improve tumor response and survival and delay time to treatment in patients with cancer who are vitamin D insufficient.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Burkitt Lymphoma, Others
      Must Be Taking:Vitamin D

      565 Participants Needed

      Oral LOXO-305 for Chronic Lymphocytic Leukemia

      Scottsdale, Arizona
      This trial is testing pirtobrutinib, a tablet taken by mouth, in patients with certain types of blood cancers who haven't responded to or can't tolerate usual treatments. The medication works by blocking a protein that cancer cells need to grow. The study aims to find the best dose and see how well it works.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, HIV, CNS Involvement, Others
      Must Not Be Taking:Warfarin, Strong CYP3A4 Inhibitors

      860 Participants Needed

      Why Other Patients Applied

      "I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."

      ID
      Pancreatic Cancer PatientAge: 40

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

      HZ
      Arthritis PatientAge: 78

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51
      Match to a Leukemia Trial

      Questionnaire Choice for Cancer Data Quality

      Phoenix, Arizona
      The purpose of this study is to evaluate feasibility and acceptability of completing PROs among AYAs randomized to Choice PRO vs Fixed PRO.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased
      Age:18 - 39

      Key Eligibility Criteria

      Disqualifiers:Recurrence, Second Primary Cancer, Others

      400 Participants Needed

      Ascorbic Acid + Chemotherapy for Lymphoma

      Scottsdale, Arizona
      This trial tests if adding high doses of vitamin C to standard chemotherapy can better treat certain cancers that have returned or are resistant to treatment. The goal is to see if vitamin C makes the chemotherapy more effective at killing cancer cells. The study focuses on patients with specific types of lymphoma, CCUS, and CMML. High-dose intravenous vitamin C (IVC) has been explored for its potential to enhance the effectiveness of cancer chemotherapy, with some clinical evidence suggesting benefits, though rigorous data are lacking.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Active Infection, Heart Failure, Others
      Must Be Taking:Platinum-based Regimens

      80 Participants Needed

      Nemtabrutinib for Blood Cancers

      Scottsdale, Arizona
      This trial is testing a new pill called nemtabrutinib for patients with blood cancers that have returned or didn't respond to other treatments. The goal is to find a safe and effective dose of the drug. Nemtabrutinib is a new drug being tested for blood cancers, designed to reduce adverse effects.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Active CNS Involvement, Uncontrolled Illness, Others
      Must Not Be Taking:CYP2C8 Substrates, P-gp Substrates, CYP3A Inducers

      190 Participants Needed

      Q702 for Blood Cancer

      Scottsdale, Arizona
      This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood cells. Giving Q702 may be safe, tolerable and/or effective in treating patients with hematologic malignancies.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Active Infections, Cardiac Disease, Others
      Must Not Be Taking:CYP Inhibitors, Herbal Supplements

      46 Participants Needed

      Modified Virus Therapy for Cancer

      Scottsdale, Arizona
      This trial tests a modified virus treatment for patients with certain types of cancer that have returned or don't respond to usual treatments. The virus aims to kill cancer cells without harming normal ones. It is combined with other drugs to improve its effectiveness.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Uncontrolled Infection, Active Tuberculosis, Hepatitis, Others
      Must Not Be Taking:Chemotherapy, Immunotherapy, Experimental Agents

      127 Participants Needed

      Relatlimab + Nivolumab for Lymphoma

      Phoenix, Arizona
      This trial is testing two drugs, relatlimab and nivolumab, in children and young adults whose lymphoma has come back or didn't respond to other treatments. These drugs help the immune system recognize and attack cancer cells. The study aims to see if this combination is safe and effective. Nivolumab has demonstrated clinical benefits in multiple tumors, including classical Hodgkin lymphoma.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2
      Age:< 30

      Key Eligibility Criteria

      Disqualifiers:CNS Lymphoma, Autoimmune Disease, Others
      Must Not Be Taking:Anti-CTLA-4, LAG-3 Agents

      68 Participants Needed

      Ruxolitinib + Chemotherapy for Leukemia

      Phoenix, Arizona
      This is a nonrandomized study of ruxolitinib in combination with a standard multi-agent chemotherapy regimen for the treatment of B-cell acute lymphoblastic leukemia. Part 1 of the study will optimize the dose of study drug (ruxolitinib) in combination with the chemotherapy regimen. Part 2 will evaluate the efficacy of combination chemotherapy and ruxolitinib at the recommended dose determined in Part 1.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:1 - 21

      Key Eligibility Criteria

      Disqualifiers:Down Syndrome, Ph+ ALL, Others

      171 Participants Needed

      Stem Cell Transplantation for Leukemia

      Phoenix, Arizona
      This phase III trial compares hematopoietic (stem) cell transplantation (HCT) using mismatched related donors (haploidentical \[haplo\]) versus matched unrelated donors (MUD) in treating children, adolescents, and young adults with acute leukemia or myelodysplastic syndrome (MDS). HCT is considered standard of care treatment for patients with high-risk acute leukemia and MDS. In HCT, patients are given very high doses of chemotherapy and/or radiation therapy, which is intended to kill cancer cells that may be resistant to more standard doses of chemotherapy; unfortunately, this also destroys the normal cells in the bone marrow, including stem cells. After the treatment, patients must have a healthy supply of stem cells reintroduced or transplanted. The transplanted cells then reestablish the blood cell production process in the bone marrow. The healthy stem cells may come from the blood or bone marrow of a related or unrelated donor. If patients do not have a matched related donor, doctors do not know what the next best donor choice is. This trial may help researchers understand whether a haplo related donor or a MUD HCT for children with acute leukemia or MDS is better or if there is no difference at all.
      No Placebo Group
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 3
      Age:6 - 21

      Key Eligibility Criteria

      Disqualifiers:Genetic Disorders, Pregnancy, Uncontrolled Infections, Others

      435 Participants Needed

      Trametinib for Juvenile Myelomonocytic Leukemia

      Phoenix, Arizona
      This phase II trial studies how well trametinib works in treating patients with juvenile myelomonocytic leukemia that has come back (relapsed) or does not respond to treatment (refractory). Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2
      Age:1 - 21

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Breastfeeding, Uncontrolled Infection, Others
      Must Not Be Taking:Corticosteroids, Investigational Drugs

      10 Participants Needed

      Venetoclax + Chemotherapy for Acute Myeloid Leukemia

      Phoenix, Arizona
      This trial is testing whether adding venetoclax to standard chemotherapy can help young patients with relapsed AML. Venetoclax works by blocking a protein that helps cancer cells survive, making it easier for the chemotherapy to kill them. The study aims to find better treatment options for these patients who have limited choices. Venetoclax has been shown to improve overall survival in older and unfit patients with newly diagnosed acute myeloid leukemia when combined with lower intensity therapies.
      No Placebo Group
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:29 - 21

      Key Eligibility Criteria

      Disqualifiers:Down Syndrome, APL, JMML, Others
      Must Not Be Taking:CYP3A Inducers

      98 Participants Needed

      12345

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial

      Frequently Asked Questions

      How much do Leukemia clinical trials in Tucson, AZ pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Leukemia clinical trials in Tucson, AZ work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Leukemia trials in Tucson, AZ 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Tucson, AZ for Leukemia is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Tucson, AZ several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Leukemia medical study in Tucson, AZ?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Leukemia clinical trials in Tucson, AZ?

      Most recently, we added Pirtobrutinib for Chronic Lymphocytic Leukemia, DLI-X for Leukemia and Asparaginase Erwinia Chrysanthemi + Chemotherapy for Blood Cancer to the Power online platform.

      Popular Searches

      By Condition

      Depression Clinical Trials in Arizona

      Anxiety Clinical Trials in Arizona

      Schizophrenia Clinical Trials in Arizona

      ADHD Clinical Trials in Arizona

      Bipolar Disorder Clinical Trials in Arizona

      Multiple Sclerosis Clinical Trials in Arizona

      Autism Clinical Trials in Arizona

      Treatment Resistant Depression Clinical Trials in Arizona

      Borderline Personality Disorder Clinical Trials in Arizona

      Social Anxiety Disorder Clinical Trials in Arizona

      Parkinson's Disease Clinical Trials in Arizona

      Alzheimer's Disease Clinical Trials in Arizona

      By Location

      Clinical Trials near Phoenix, AZ

      Clinical Trials near Tucson, AZ

      Clinical Trials near Scottsdale, AZ

      Clinical Trials near Mesa, AZ

      Clinical Trials near Chandler, AZ

      Clinical Trials near Tempe, AZ

      Clinical Trials near Gilbert, AZ

      Clinical Trials near Glendale, AZ

      Clinical Trials near Peoria, AZ

      Clinical Trials near Sun City, AZ

      Clinical Trials near Goodyear, AZ

      Clinical Trials near Flagstaff, AZ

      Other People Viewed

      By Subject

      8 Weight Loss Trials near Tampa, FL

      Top Bowel Cancer Clinical Trials

      Top Clinical Trials near Georgia

      Top Clinical Trials near Cutler Bay, FL

      134 Clinical Trials near Greensburg, PA

      Top Anesthesia Clinical Trials

      Top Clinical Trials near Bayside, NY

      119 Clinical Trials near Bath, ME

      Top Clinical Trials near Saint Louis Park, MN

      Top Clinical Trials near Kernersville, NC

      Top Clinical Trials near Germantown, MD

      Top Clinical Trials near Arizona

      By Trial

      Lenvatinib + Pembrolizumab for Breast Cancer

      Acoramidis for Amyloidosis

      Egg Supplementation for Infant Cognitive Development During Breastfeeding

      AMG 691 for Asthma

      Outpatient Foley Catheter for Induction of Labor

      Dupilumab for Atopic Dermatitis

      Vaccine + Chemotherapy for Head and Neck Cancer

      AZD0486 + Rituximab for Follicular Lymphoma

      Brain Stimulation for Nicotine Addiction in Schizophrenia

      Virtual Reality Technology for Head and Neck Cancer

      Academic Detailing for Rheumatoid Arthritis

      Egg White Protein Pudding for Kidney Failure